Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.65 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.65 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.59 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.58 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.58 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104598 | 0.98 | KDM4E (0.73) | KDM4EALDH1A1SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL30160092 | 0.98 | KDM4E (0.73) | KDM4EALDH1A1SMN1; SMN2HTR2AHTR2C | |
| Bromide SCHEMBL8568783 | 0.96 | KDM4E (0.71) | KDM4EALDH1A1SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL14156164 | 0.96 | SMN1; SMN2 (0.74) | KDM4EALDH1A1SMN1; SMN2HTR2AHTR2C | |
| Ammonia Solution, Strong SCHEMBL28165982 | 0.96 | KDM4E (0.71) | KDM4EALDH1A1SMN1; SMN2HTR2AHTR2C | |
| Iodide SCHEMBL8569085 | 0.96 | KDM4E (0.71) | KDM4EALDH1A1SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL15266076 | 0.96 | KDM4E (0.71) | KDM4EALDH1A1SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL11641810 | 0.96 | SMN1; SMN2 (0.74) | KDM4EALDH1A1SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL7402531 | 0.96 | KDM4E (0.71) | KDM4EALDH1A1SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL30657796 | 0.96 | SMN1; SMN2 (0.74) | KDM4EALDH1A1SMN1; SMN2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1693366-A1 | Selective 5-HT 6 receptor ligands | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20040132800-A1 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN (US) | 2004-07-08 | — | — | US | disclosed |
| US-6518297-B2 | Serotonin (5-HT) subtype 6 receptor (5-HT6); 3-(2-aminoethyl)indole derivatives; drug screening | VIRGINIA COMMONWEALTH UNIVERSITY | 2003-02-11 | — | — | US | disclosed |
| EP-1149078-A4 | SELECTIVE 5-HT 6? RECEPTOR LIGANDS | UNIV VIRGINIA COMMONWEALTH (US) | 2003-01-29 | — | — | EP | disclosed |
| US-6489488-B2 | SEROTONIN (5-HT) SUBTYPE 6 RECEPTOR (5-HT6); 3-(2-AMINOETHYL)INDOLE DERIVATIVES; DRUG SCREENING | VIRGINIA COMMONWEALTH UNIVERSITY | 2002-12-03 | — | — | US | disclosed |
| US-20020103382-A1 | Selective 5-HT6 receptor ligands | GLENNON RICHARD A (US) | 2002-08-01 | — | — | US | disclosed |
| US-20020103383-A1 | Selective 5-HT6 receptor ligands | GLENNON RICHARD A (US) | 2002-08-01 | — | — | US | disclosed |
| US-6403808-B1 | TREATING MENTAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY | 2002-06-11 | — | — | US | disclosed |
| EP-1149078-A1 | SELECTIVE 5-HT 6? RECEPTOR LIGANDS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000034242-A1 | SELECTIVE 5-HT6 RECEPTOR LIGANDS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-1998055115-A1 | CARBOXAMIDES USEFUL AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1998-12-10 | — | — | WO | disclosed |
| WO-1998011895-A1 | A METHOD FOR THE PREVENTION OF MIGRAINE | ELI LILLY AND COMPANY (US) | 1998-03-26 | — | — | WO | disclosed |
| WO-1998006402-A1 | TREATMENT OF THE COMMON COLD OR ALLERGIC RHINITIS | ELI LILLY AND COMPANY (US) | 1998-02-19 | — | — | WO | disclosed |
| EP-0674621-A1 | ENANTIOMERS OF CARBAZOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994014772-A1 | ENANTIOMERS OF CARBAZOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103382-A1 | Selective 5-HT6 receptor ligands | HTR6, HTR4, HTR5A | HTR2A 7/4885HTR2C 8/4885PARP1 4333/4885 |
| US-20040132800-A1 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR1B, HTR1A | HTR2A 5/4885HTR2C 4/4885PARP1 1945/4885 |
| US-20020103383-A1 | Selective 5-HT6 receptor ligands | HTR6, HTR4, HTR5A | HTR2A 7/4885HTR2C 8/4885PARP1 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.